Nexalin Technology, Inc. (NXL) research
Nexalin Technology, Inc.- Sector
- Healthcare
- Industry
- Medical Devices
- Last price
- $5.73
- As of
Nexalin Technology, Inc. (NXL): 1 institutional manager tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-10-01.
As of . Source: SEC EDGAR filings for NXL. Method and limitations.
Share the NXL intelligence card
See the full NXL dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for NXL on one page. Preview it with sample data, then open it live with a free account.
Preview the NXL dossierActive signals for NXL
- mediumEARNINGS_MISS
Q2-2026: Missed consensus by 8.9%, EPS $-3.30 vs $-3.03 estimate
- highINSTITUTIONAL_SURGE
CITADEL ADVISORS LLC added +144% to NXL (2026Q2)
- highINSTITUTIONAL_EXIT
RENAISSANCE TECHNOLOGIES LLC cut 91% of NXL (2026Q1)
- mediumEARNINGS_MISS
Q3-2025: Missed consensus by 7.3% - EPS $-0.13 vs $-0.1212 estimate
- mediumEARNINGS_MISS
Q1-2026: Missed consensus by 8.9% - EPS $-0.11 vs $-0.101 estimate
FREE, NO ACCOUNT
Every signal on NXL, as it fires
You are seeing 5 of 8 signals recorded on NXL since 2026-05-31.
The five above landed across 4 days. The other 3 were recorded on 1 other days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in NXL (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| CITADEL ADVISORS LLCCUSIP 65345B201 · 2026Q2 | $25K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, NXL
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
NXL against its peers
NXL's operating margin of -2781.7% ranks in the 17th percentile of 14 Medical Devices sub-industry peers, fiscal periods ending between 2025-12-31 and 2026-06-30.
| Metric | NXL | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 301647 USD | 2.7M USD | 22 | 15 |
| Gross margin | 79.7% | 59.8% | 88 | 11 |
| Operating margin | -2781.7% | -231.0% | 17 | 14 |
| Net margin | -2725.8% | -306.6% | 17 | 14 |
| Return on equity | -219.4% | -202.3% | 46 | 13 |
Peers (18): ADGM, AEMD, STME, USAQ, ITOC, POAS, VVOS, AIDX, XAIR, RMSL, INBS, NUWE, ADMT, IVF, VYCO, NVNO, TNON, VNRX. Left out: PMEDF (period gap), CYDX (no annual filing), TRIB (period gap), KLYG (no annual filing), CSDX (no annual filing), FZMD (period gap), SONX (period gap). Fiscal periods ending between 2025-12-31 and 2026-06-30. Every figure is one full fiscal year read from one annual filing (NXL: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
See more NXL signals as they fire
Kresmion publishes filings, 13F flows, on-chain whale activity, and cross-asset signals in real time. Open a live board scoped to NXLand get the insider, 13F, options, and confluence read in one view.